Target Name: GPR182
NCBI ID: G11318
Other Name(s): Adrenomedullin receptor | 7TMR | ADMR | G-protein coupled receptor 182 | Gamrh | L1-R | adrenomedullin receptor | AM-R | GP182_HUMAN | G protein-coupled receptor 182 | AMR | G10D | hrhAMR | gamrh | MGC34399

GPR182: A GPCR Targeted for Pain Management and Neurodegenerative Diseases

GPR182 is a G protein-coupled receptor that is expressed in various tissues and cells throughout the body. It is a key regulator of pain perception and neuropeptide signaling, and its dysfunction has been implicated in a number of neuropsychiatric and neurological disorders. In this article, we will discuss GPR182 as a drug target and its potential for clinical applications.

GPR182: Structure and Function

GPR182 is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a critical role in cellular signaling. GPCRs are characterized by the presence of a transmembrane domain, a catalytic domain, and a carboxylic acid terminator.

GPR182 is a 14kDa protein that is expressed in the central nervous system (CNS), including the brain, spinal cord, and peripheral tissues. It is primarily expressed in the diencephalon, which is the part of the brain that controls movement, sensation, and cognition. GPR182 is also expressed in the hypothalamus, which is a region of the brain that regulates hunger and thirst.

GPR182 is involved in the regulation of pain perception and neuropeptide signaling. It is a critical regulator of the neurotransmitter serotonin, which is involved in pain modulation. GPR182 is also involved in the regulation of neuropeptides, such as oxytocin and endothelin, which are involved in maternal bonding, pain modulation, and neuroendocrine regulation.

Dysfunction of GPR182

GPR182 dysfunction has been implicated in a number of neuropsychiatric and neurological disorders, including chronic pain, anxiety, and depression. Studies have shown that GPR182 dysfunction is associated with increased pain sensitivity, increased anxiety and depression-like behavior, and decreased neuroendocrine regulation.

GPR182 has also been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that GPR182 dysfunction is associated with increased neurodegeneration, decreased neuroprotective enzymes, and increased oxidative stress.

GPR182 as a Drug Target

GPR182 is a potential drug target due to its involvement in pain perception and neuropeptide signaling. Studies have shown that GPR182 is involved in the regulation of pain modulation, and that inhibition of GPR182 can reduce pain sensitivity. This suggests that GPR182 could be an effective target for pain management therapies.

GPR182 is also involved in the regulation of neuropeptide signaling, and its dysfunction has been implicated in the development and progression of neurodegenerative diseases. Therefore, GPR182 could also be an effective target for neurodegenerative disease therapies.

GPR182 has also been shown to be involved in the regulation of maternal bonding and neuroendocrine regulation. Therefore, GPR182 could also be a potential target for therapies that target these processes.

Conclusion

GPR182 is a GPCR that is involved in the regulation of pain perception and neuropeptide signaling. Its dysfunction has been implicated in a number of neuropsychiatric and neurological disorders, including chronic pain, anxiety, and depression. Therefore, GPR182 is a potential drug target for pain management therapies, neurodegenerative disease therapies, and therapies that target maternal bonding and neuroendocrine regulation.

Future studies are needed to fully understand the role of GPR182 in pain perception and neuropeptide signaling, and to determine its potential as a drug target.

Protein Name: G Protein-coupled Receptor 182

Functions: Orphan receptor

More Common Targets

GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7 | Granzyme | GRAP | GRAP2 | GRAPL | GRAPL-AS1 | GRASLND | GRB10 | GRB14 | GRB2 | GRB7 | GREB1 | GREB1L | GREM1 | GREM1-AS1 | GREM2 | GREP1 | GRHL1